International, multicentre, observational study of fluid bolus therapy in neonates

Amy K. Keir, Oliver Karam, Nicolette Hodyl, Michael J. Stark, Helen G. Liley, Prakesh S. Shah, Simon J. Stanworth, on behalf of the NeoBolus Study Group

Research output: Contribution to journalArticle

Abstract

Aim: To assess the prevalence, types and indications for fluid bolus therapy in neonates with haemodynamic compromise. Methods: This was a pragmatic, international, multicentre observational study in neonatal units across Australasia, Europe and North America with a predefined study period of 10–15 study days per participating neonatal unit between December 2015 and March 2017. Infants ≤28 days of age who received a fluid bolus for the management of haemodynamic compromise (≥10 mL/kg given at ≤6 h) were included. Results: A total of 163 neonates received a bolus over 8479 eligible patient days in 41 neonatal units. Prevalence of fluid bolus therapy varied between centres from 0 to 28.6% of admitted neonates per day, with a pooled prevalence rate of 1.5% (95% confidence interval 1.1–1.9%). The most common fluid used was 0.9% sodium chloride (129/163; 79%), and the volume of fluid administered was most commonly 10 mL/kg (115/163; 71%) over a median of 30 min (interquartile range 20–60). The most frequent indications were hypotension (n = 56; 34%), poor perfusion (n = 20; 12%) and metabolic acidosis (n = 20; 12%). Minimal or no clinical improvement was reported by clinicians in 66 of 163 cases (40%). Conclusions: Wide international variations in types, indications and effects of fluid bolus administration in haemodynamically compromised neonates suggest uncertainty in the risk–benefit profile. This is likely to reflect the lack of robust evidence to support the efficacy of different fluid types, doses and appropriate indications. Together, these highlight a need for further clinically relevant studies.

LanguageEnglish
Pages632-639
Number of pages8
JournalJournal of Paediatrics and Child Health
Volume55
Issue number6
DOIs
Publication statusPublished - 1 Jun 2019

Keywords

  • blood pressure
  • fluid
  • infant
  • newborn
  • therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Keir, A. K., Karam, O., Hodyl, N., Stark, M. J., Liley, H. G., Shah, P. S., ... on behalf of the NeoBolus Study Group (2019). International, multicentre, observational study of fluid bolus therapy in neonates. Journal of Paediatrics and Child Health, 55(6), 632-639. https://doi.org/10.1111/jpc.14260
Keir, Amy K. ; Karam, Oliver ; Hodyl, Nicolette ; Stark, Michael J. ; Liley, Helen G. ; Shah, Prakesh S. ; Stanworth, Simon J. ; on behalf of the NeoBolus Study Group. / International, multicentre, observational study of fluid bolus therapy in neonates. In: Journal of Paediatrics and Child Health. 2019 ; Vol. 55, No. 6. pp. 632-639.
@article{4f157224b1db443eadfb0297d36bf436,
title = "International, multicentre, observational study of fluid bolus therapy in neonates",
abstract = "Aim: To assess the prevalence, types and indications for fluid bolus therapy in neonates with haemodynamic compromise. Methods: This was a pragmatic, international, multicentre observational study in neonatal units across Australasia, Europe and North America with a predefined study period of 10–15 study days per participating neonatal unit between December 2015 and March 2017. Infants ≤28 days of age who received a fluid bolus for the management of haemodynamic compromise (≥10 mL/kg given at ≤6 h) were included. Results: A total of 163 neonates received a bolus over 8479 eligible patient days in 41 neonatal units. Prevalence of fluid bolus therapy varied between centres from 0 to 28.6{\%} of admitted neonates per day, with a pooled prevalence rate of 1.5{\%} (95{\%} confidence interval 1.1–1.9{\%}). The most common fluid used was 0.9{\%} sodium chloride (129/163; 79{\%}), and the volume of fluid administered was most commonly 10 mL/kg (115/163; 71{\%}) over a median of 30 min (interquartile range 20–60). The most frequent indications were hypotension (n = 56; 34{\%}), poor perfusion (n = 20; 12{\%}) and metabolic acidosis (n = 20; 12{\%}). Minimal or no clinical improvement was reported by clinicians in 66 of 163 cases (40{\%}). Conclusions: Wide international variations in types, indications and effects of fluid bolus administration in haemodynamically compromised neonates suggest uncertainty in the risk–benefit profile. This is likely to reflect the lack of robust evidence to support the efficacy of different fluid types, doses and appropriate indications. Together, these highlight a need for further clinically relevant studies.",
keywords = "blood pressure, fluid, infant, newborn, therapy",
author = "Keir, {Amy K.} and Oliver Karam and Nicolette Hodyl and Stark, {Michael J.} and Liley, {Helen G.} and Shah, {Prakesh S.} and Stanworth, {Simon J.} and {on behalf of the NeoBolus Study Group}",
year = "2019",
month = "6",
day = "1",
doi = "10.1111/jpc.14260",
language = "English",
volume = "55",
pages = "632--639",
journal = "Journal of Paediatrics and Child Health",
issn = "1034-4810",
publisher = "Wiley-Blackwell",
number = "6",

}

Keir, AK, Karam, O, Hodyl, N, Stark, MJ, Liley, HG, Shah, PS, Stanworth, SJ & on behalf of the NeoBolus Study Group 2019, 'International, multicentre, observational study of fluid bolus therapy in neonates', Journal of Paediatrics and Child Health, vol. 55, no. 6, pp. 632-639. https://doi.org/10.1111/jpc.14260

International, multicentre, observational study of fluid bolus therapy in neonates. / Keir, Amy K.; Karam, Oliver; Hodyl, Nicolette; Stark, Michael J.; Liley, Helen G.; Shah, Prakesh S.; Stanworth, Simon J.; on behalf of the NeoBolus Study Group.

In: Journal of Paediatrics and Child Health, Vol. 55, No. 6, 01.06.2019, p. 632-639.

Research output: Contribution to journalArticle

TY - JOUR

T1 - International, multicentre, observational study of fluid bolus therapy in neonates

AU - Keir, Amy K.

AU - Karam, Oliver

AU - Hodyl, Nicolette

AU - Stark, Michael J.

AU - Liley, Helen G.

AU - Shah, Prakesh S.

AU - Stanworth, Simon J.

AU - on behalf of the NeoBolus Study Group

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Aim: To assess the prevalence, types and indications for fluid bolus therapy in neonates with haemodynamic compromise. Methods: This was a pragmatic, international, multicentre observational study in neonatal units across Australasia, Europe and North America with a predefined study period of 10–15 study days per participating neonatal unit between December 2015 and March 2017. Infants ≤28 days of age who received a fluid bolus for the management of haemodynamic compromise (≥10 mL/kg given at ≤6 h) were included. Results: A total of 163 neonates received a bolus over 8479 eligible patient days in 41 neonatal units. Prevalence of fluid bolus therapy varied between centres from 0 to 28.6% of admitted neonates per day, with a pooled prevalence rate of 1.5% (95% confidence interval 1.1–1.9%). The most common fluid used was 0.9% sodium chloride (129/163; 79%), and the volume of fluid administered was most commonly 10 mL/kg (115/163; 71%) over a median of 30 min (interquartile range 20–60). The most frequent indications were hypotension (n = 56; 34%), poor perfusion (n = 20; 12%) and metabolic acidosis (n = 20; 12%). Minimal or no clinical improvement was reported by clinicians in 66 of 163 cases (40%). Conclusions: Wide international variations in types, indications and effects of fluid bolus administration in haemodynamically compromised neonates suggest uncertainty in the risk–benefit profile. This is likely to reflect the lack of robust evidence to support the efficacy of different fluid types, doses and appropriate indications. Together, these highlight a need for further clinically relevant studies.

AB - Aim: To assess the prevalence, types and indications for fluid bolus therapy in neonates with haemodynamic compromise. Methods: This was a pragmatic, international, multicentre observational study in neonatal units across Australasia, Europe and North America with a predefined study period of 10–15 study days per participating neonatal unit between December 2015 and March 2017. Infants ≤28 days of age who received a fluid bolus for the management of haemodynamic compromise (≥10 mL/kg given at ≤6 h) were included. Results: A total of 163 neonates received a bolus over 8479 eligible patient days in 41 neonatal units. Prevalence of fluid bolus therapy varied between centres from 0 to 28.6% of admitted neonates per day, with a pooled prevalence rate of 1.5% (95% confidence interval 1.1–1.9%). The most common fluid used was 0.9% sodium chloride (129/163; 79%), and the volume of fluid administered was most commonly 10 mL/kg (115/163; 71%) over a median of 30 min (interquartile range 20–60). The most frequent indications were hypotension (n = 56; 34%), poor perfusion (n = 20; 12%) and metabolic acidosis (n = 20; 12%). Minimal or no clinical improvement was reported by clinicians in 66 of 163 cases (40%). Conclusions: Wide international variations in types, indications and effects of fluid bolus administration in haemodynamically compromised neonates suggest uncertainty in the risk–benefit profile. This is likely to reflect the lack of robust evidence to support the efficacy of different fluid types, doses and appropriate indications. Together, these highlight a need for further clinically relevant studies.

KW - blood pressure

KW - fluid

KW - infant

KW - newborn

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85055026638&partnerID=8YFLogxK

U2 - 10.1111/jpc.14260

DO - 10.1111/jpc.14260

M3 - Article

VL - 55

SP - 632

EP - 639

JO - Journal of Paediatrics and Child Health

T2 - Journal of Paediatrics and Child Health

JF - Journal of Paediatrics and Child Health

SN - 1034-4810

IS - 6

ER -